Harrow, Inc. (NASDAQ:HROW) Receives $71.14 Consensus PT from Analysts

Shares of Harrow, Inc. (NASDAQ:HROW) have earned a consensus rating of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $71.1429.

A number of equities analysts have recently commented on the stock. William Blair reissued an “outperform” rating on shares of Harrow in a report on Tuesday, March 3rd. Cantor Fitzgerald dropped their price objective on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Zacks Research lowered shares of Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 3rd. HC Wainwright increased their target price on Harrow from $69.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research report on Thursday, January 22nd.

Harrow Trading Up 2.4%

Shares of HROW opened at $34.91 on Friday. The firm’s 50 day simple moving average is $45.83 and its 200 day simple moving average is $43.64. The company has a market capitalization of $1.30 billion, a P/E ratio of -205.34 and a beta of 0.05. The company has a debt-to-equity ratio of 4.67, a current ratio of 2.20 and a quick ratio of 2.06. Harrow has a 1-year low of $20.85 and a 1-year high of $54.85.

Hedge Funds Weigh In On Harrow

A number of large investors have recently modified their holdings of the company. Larson Financial Group LLC lifted its position in Harrow by 13.1% in the 4th quarter. Larson Financial Group LLC now owns 2,446 shares of the company’s stock worth $120,000 after buying an additional 284 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Harrow by 2.1% in the second quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock worth $505,000 after buying an additional 341 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Harrow by 25.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after acquiring an additional 369 shares during the last quarter. Captrust Financial Advisors grew its position in Harrow by 0.5% during the fourth quarter. Captrust Financial Advisors now owns 69,959 shares of the company’s stock valued at $3,428,000 after acquiring an additional 376 shares during the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of Harrow by 1.7% during the third quarter. Alliancebernstein L.P. now owns 29,520 shares of the company’s stock worth $1,422,000 after acquiring an additional 500 shares in the last quarter. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.